CIA
PTCT icon

Cladis Investment Advisory’s PTC Therapeutics PTCT Stock Holding History

Cladis Investment Advisory’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$343K Hold
4,200
– – 0.16% 125
2026
Q1 		$286K Hold
4,200
– – 0.16% 125
2025
Q4 		$319K Sell
4,200
-1,000
-19% -$72.7K 0.17% 118
2025
Q3 		$319K Hold
5,200
– – 0.18% 119
2025
Q2 		$254K Buy
5,200
+1,200
+30% +$57K 0.16% 121
2025
Q1 		$204K Buy
+4,000
New +$200K 0.15% 125

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Cladis Investment Advisory's PTCT Position: Q2 2026 in Review

Cladis Investment Advisory held its PTC Therapeutics (PTCT) position steady in Q2 2026 at 4,200 shares worth $343K. The position accounts for 0.16% of the portfolio, ranked #125.

Cladis Investment Advisory first reported a position in PTCT in Q1 2025 and has held it in 6 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Cladis Investment Advisory held 4,200 shares of PTC Therapeutics worth $343K as of Q2 2026.
  • Cladis Investment Advisory left its PTC Therapeutics share count unchanged in Q2 2026.
  • PTC Therapeutics made up 0.16% of Cladis Investment Advisory's portfolio in Q2 2026, its #125 holding.
  • Cladis Investment Advisory first reported a position in PTC Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Cladis Investment Advisory's 13F filing for Q2 2026, filed 13 Aug 2026.